Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

Case Western Reserve University

Other

The General Hospital Corporation

Stephen J Lippard

Patti Jean Kellett

John M Essigmann

Jeffrey H Toney

Brian A Donahue

Pieter M Pil

Suzanne L Bruhn

Omid C Farokhzad

Steven J Brown

Shanta Dhar

Elizabeth Marie Nolan

Gilberto M Villacorta

Robert J Radford

Kwang-Hyun Ahn

Nicole F Steinmetz

Frank X Gu

Justin J Wilson

Nagesh Kolishetti

Christopher J Ziegler

Shawn Burdette

Kogularamanan Suntharalingam

Anna Czapar

Patricia A Bianconi

Yaorong Zheng

Robert Samuel Langer

Roger Y Tsien

Christopher J Chang

Rohit Nandkumar Karnik

Anna V Moore

Evgeny A Nudler

Omer Yilmaz

Zdravka Medarova

Ariel Haskel

Matthew D Shoulders

Alan Pradip Jasanoff

Pedro M Valencia

Scott Hilderbrand

Steven Joel Brown

Stefanie A Kane

Jonathan Braverman

Xiao-an Zhang

Fang Wang

Ying Song

Ga Young Park

Lisa S Cunden

Lindsey E McQuade

Xiao-An Zhang

Mi Hee Lim

Carolyn Crystal Woodroofe

Grant K Walkup

Carmen M Barnes

Eric M Pridgen

Katie R Barnes

Suresh Gadde

Raymond N Vrtis

Wen Chyan

Chebrolu P Rao

Bruce E Bowler

Christopher E R Richardson

Maria R Chan

Daniel Y Zhang

Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.

Anticancer drug-containing plant virus particles

Platinum-containing compounds are generally described. For example, compounds of Formula (II) are generally described. Inventive compositions and uses thereof are also described. For example, methods of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of Formula (II) are generally described. 

Platinum-containing compounds, and related compositions and uses thereof

Compositions and methods for the selective sequestration of metal ions are generally described.

Compositions and methods for selectively sequestering metal ions

Compositions and methods comprising osmium are provided. In some embodiments, the osmium compounds comprise a bidentate ligand. In some embodiments, the osmium compounds are used in method for treating cancer.

Compositions and methods comprising osmium for the treatment of cancers

Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles.

Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use

Disclosed are compounds and methods useful in the detection of e.g., Zn, in vitro and in vivo. The compounds include amino acids and peptides functionalized with a moiety that binds, e.g., Zn. Importantly, the compounds do not exhibit substantial fluorescence in the absence of zinc.

Reaction-based fluorescent probes for detecting zinc

Compositions, kits, and methods for treatment of cancers are generally provided. In some embodiments, the compositions, kits, and methods comprise a platinum (e.g., Pt(II) or Pt(IV)) compound associated with a ligand (e.g., a beta-diketonate ligand) comprising a targeting moiety. Methods of synthesizing platinum (e.g., Pt(II) or Pt(IV)) compounds associated with a ligand comprising a targeting moiety are also provided.

Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety

The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects in need of therapeutic protocol, including subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a first component comprising a precursor to a therapeutically active platinum agent and a precursor to a second therapeutically active agent. The therapeutically active platinum agent and the second therapeutically active agent may dissociate from each other, thereby forming a first therapeutically active platinum agent and a second therapeutically active agent. The second therapeutically active gent may affect a cellular pathway of a cancer cell and may be substantially inactive towards non-cancerous cells.

Platinum (IV) complexes for use in dual mode pharmaceutical therapy

Methods, compounds, and compositions for treating a proliferative disorder or other physiological conditions via a dual targeting anticancer therapy are provided. In some embodiments, a dual targeting anticancer therapy may utilize a composition comprising a platinum agent. The platinum agent may comprise a precursor to a therapeutically active platinum compound and at least one precursor to a vitamin E agent. The vitamin E agent may target cancer cells via a different mechanism of action than the therapeutically active platinum compound resulting in a dual targeting anticancer agent. The method of treatment may involve administering to a patient the dual targeting anticancer agent. Following administration, a therapeutically active platinum compound and a vitamin E agent may form at the physiologically relevant site. In some embodiments, administering a platinum agent comprising precursors of therapeutically active agents may be more effective than individually or simultaneously administering separate molecules of those therapeutically active agents.

Dual targeting anticancer agents

The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand.

Compositions and methods for the treatment of cancer

The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.

Nanostructures for drug delivery

Described herein are compounds and methods useful in the detection of, e.g., Zn, in vitro and in vivo. The compounds include amino acids and peptides functionalized with a moiety that binds, e.g., Zn. The peptides may be further functionalized with a detectable moiety. The peptides may also comprise amino acid sequences known to localize extracellularly or in specific areas within a cell.

Zinc-responsive peptides, and methods of use thereof

The present invention is a platinum(II) compound comprising a beta-diketonate ligand represented by the following general formula:   These compounds are useful in the treatment of cancer.

Platinum compounds as treatment for cancers, and related methods, kits, and compositions

The invention relates in part to compounds that act as highly nitric oxide (NO)-specific turn-on fluorescent probes. The present invention also relates to the use of these fluorescein-based sensors to screen selectively for inhibitors of bacterial nitric oxide synthase (bNOS). Compounds of the present invention readily detect nitric oxide produced in vivo. Therefore they can be used in an assay that measures NO production by bNOS. Using a sensor of the invention one can screen libraries of small molecules for inhibitors of bNOS.

Inhibitors of bacterial nitric oxide synthase, and related screening methods

Growing community of inventors

Cambridge, MA, United States of America

Stephen J Lippard